Status:
COMPLETED
Phenotypic Spectrum of CTCs in Tumors of the Female Reproductive System
Lead Sponsor:
Tomsk National Research Medical Center of the Russian Academy of Sciences
Conditions:
Breast Cancer
Ovarian Cancer
Eligibility:
FEMALE
18-80 years
Brief Summary
The study evaluates the level and molecular profiles of different CTC populations as markers for predicting the risk of developing hematogenous metastases and the effectiveness of treatment in patient...
Detailed Description
The overall goal is to study the diagnostic and prognostic efficacy of various CTC populations as liquid biopsy markers in tumors of the female reproductive system (breast cancer, endometrial cancer, ...
Eligibility Criteria
Inclusion
- Subject is \> 18 years of age A negative pregnancy test (serum beta-human chorionic gonadotropin, beta-HCG) at screening for all patients of childbearing potential.
- Clinical and radiological diagnosis of breast cancer or Ovarian cancer or Endometrial Cancer General satisfactory condition (according to the ECOG scale ≤2) Subject is capable to undergo the diagnostic investigations to be performed in the study
- Informed consent
Exclusion
- Active current autoimmune disease or history of autoimmune disease
- Active infection or history of severe infection within the previous 3 months (if clinically relevant at screening)
- Known HIV positive or chronically active hepatitis B or C The subject has multiple primary malignant tumors
Key Trial Info
Start Date :
February 14 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2022
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04817501
Start Date
February 14 2014
End Date
December 1 2022
Last Update
January 25 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Evgeniya Kaigorodova
Tomsk, Tomsk Oblast, Russia, 634050